deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 2-arm NCT03992456

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

PULSE: A Randomized, Phase II Open Label Study of PanitUmumab RechaLlenge Versus Standard Therapy After Progression on Anti-EGFR Therapy in Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Sponsor: Academic and Community Cancer Research United

Conditions Metastatic Colon Adenocarcinoma Metastatic Colorectal Carcinoma Metastatic Rectal Adenocarcinoma Stage III Colon Cancer AJCC v8 Stage III Colorectal Cancer AJCC v8 Stage III Rectal Cancer AJCC v8 Stage IIIA Colon Cancer AJCC v8 Stage IIIA Colorectal Cancer AJCC v8 Stage IIIA Rectal Cancer AJCC v8 Stage IIIB Colon Cancer AJCC v8 Stage IIIB Colorectal Cancer AJCC v8 Stage IIIB Rectal Cancer AJCC v8 Stage IIIC Colon Cancer AJCC v8 Stage IIIC Colorectal Cancer AJCC v8 Stage IIIC Rectal Cancer AJCC v8 Stage IV Colon Cancer AJCC v8 Stage IV Colorectal Cancer AJCC v8 Stage IV Rectal Cancer AJCC v8 Stage IVA Colon Cancer AJCC v8 Stage IVA Colorectal Cancer AJCC v8 Stage IVA Rectal Cancer AJCC v8 Stage IVB Colon Cancer AJCC v8 Stage IVB Colorectal Cancer AJCC v8 Stage IVB Rectal Cancer AJCC v8 Stage IVC Colon Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8 Stage IVC Rectal Cancer AJCC v8 Unresectable Colon Adenocarcinoma Unresectable Colorectal Carcinoma Unresectable Rectal Adenocarcinoma
Interventions Panitumumab Quality-of-Life Assessment Questionnaire Administration Regorafenib Trifluridine and Tipiracil Hydrochloride
Updated 24 times since 2019 Last updated: May 16, 2024 Started: Apr 24, 2020 Primary completion: Dec 1, 2023 Completion: Oct 7, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03992456, this PHASE2 trial focuses on Metastatic Colon Adenocarcinoma and Metastatic Colorectal Carcinoma and remains ongoing. Sponsored by Academic and Community Cancer Research United, it has been updated 24 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jul 2019 – ~Jan 2020 · 6 months · monthly snapshot~Jan 2020 – ~May 2020 · 4 months · monthly snapshot~May 2020 – ~Aug 2020 · 3 months · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Mar 2022 · 3 months · monthly snapshot~Mar 2022 – ~Jun 2022 · 3 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Feb 2023 · 3 months · monthly snapshot~Feb 2023 – ~Nov 2023 · 9 months · monthly snapshot~Nov 2023 – ~Jun 2024 · 7 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

24 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Nov 2023 — Jun 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 19 earlier versions

  1. Feb 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE2

  2. Nov 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Jun 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  5. Mar 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  6. Dec 2021 — Mar 2022 [monthly]

    Recruiting PHASE2

  7. Sep 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  8. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  9. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  10. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE2

  11. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  12. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  13. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  14. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  15. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  16. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE2

  17. May 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  18. Jan 2020 — May 2020 [monthly]

    Not Yet Recruiting PHASE2

  19. Jul 2019 — Jan 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Academic and Community Cancer Research United
  • National Cancer Institute (NCI)
Data source: Academic and Community Cancer Research United

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Boston, United States , Chicago, United States , Durham, United States , Houston, United States , Jacksonville, United States , La Jolla, United States , Los Angeles, United States , New Brunswick, United States , Pittsburgh, United States and 4 more locations